Loading...
Obesity Drug Patent Expires Today: Prices Could Drop to Rs 500, What This Game Changer Means
LIVE TV
LOCAL
Tour
ENGLISH
For You
Entertainment
National
Sports
Markets
Business & Economy
Lifestyle
World
Astrology & Religion
Technology
Education & Jobs
Auto
Politics
Viral
Opinions
Home
Local
Live TV
Loading more articles...
Obesity Drug Patent Ends: Prices to Drop to Rs 500, A Game-Changer for India
N
News18
•
20-03-2026, 17:36
Obesity Drug Patent Ends: Prices to Drop to Rs 500, A Game-Changer for India
•
The patent for obesity medicines like Ozempic and Wegovy has expired in several countries, including India.
•
Monthly cost of these weight loss injections, currently around Rs 10,000, is expected to drop to Rs 500.
•
This price reduction is a game-changer for India, which has the highest number of people with diabetes and obesity globally.
•
Affordable medicine will increase awareness and access to treatment for the approximately 40% of obese adults in India.
•
India's expertise in generic drug manufacturing means it will produce and export these affordable weight loss medicines globally.
Read Full Article on News18 in Hindi
✦
More like this
✦
More like this
Low-Cost Anti-Obesity Drugs Coming to India as Semaglutide Patent Expires
F
Firstpost
Diabetes Treatment Revolution: Natco Pharma Launches Affordable Semaglutide in India
N
News18
Gold, Silver Prices Plunge in Hyderabad: A Relief for Buyers Amidst Market Fluctuations
N
News18
Rupee Hits Record Low, FII Outflows Persist Amid Global Tensions
C
CNBC TV18
GLP-1 Drug Price Drop: India's Obesity Treatment Access Boosted, But Challenges Remain
N
News18
Gold, Silver Prices Drop: Ugadi Gift for Hyderabad, Further Decrease Expected
N
News18
